Lyme Arthritis: Is Persistent Joint Pain Debris or Ongoing Infection?

Can Lyme disease cause persistent joint pain after treatment? New research suggests the answer may be more complex than previously thought.

For years, persistent joint inflammation after antibiotic treatment was believed to reflect an overactive immune response to leftover bacterial debris—not ongoing infection.

But emerging evidence is challenging that assumption, making joint pain an important Lyme disease symptom that deserves closer evaluation. :contentReference[oaicite:0]{index=0}

Peptidoglycan Found in Joint Fluid After Treatment

A recent study published in Science Translational Medicine examined synovial fluid from patients with Lyme arthritis—often weeks or months after diagnosis and antibiotic therapy.

Researchers identified peptidoglycan, a structural component of the Borrelia burgdorferi cell wall, persisting in joint fluid.

Peptidoglycan is known to trigger strong immune responses. Its presence has been proposed as a driver of continued inflammation—even when live bacteria are not detected.

This raises a critical question: Is this truly inert debris—or could it reflect ongoing infection?

The Current Assumption: Inflammation Without Infection

The prevailing view is that antibiotic-refractory Lyme arthritis results from immune activation triggered by residual bacterial material.

This model suggests that after infection is cleared, fragments such as peptidoglycan continue to stimulate inflammation.

If this is the case, treatment may focus on immune modulation—such as NSAIDs, corticosteroids, or DMARDs—rather than additional antibiotics.

However, this explanation depends on an assumption that deserves closer examination.

The Limitation: Detecting Live Borrelia Is Difficult

In the study, live Borrelia organisms were not detected in joint fluid.

However, absence of detectable bacteria is not evidence of absence.

Detecting Borrelia in synovial fluid or tissue is inherently challenging. The organism may exist in low numbers, within protected niches, or in forms that evade conventional testing methods.

This limitation is part of broader persistent Lyme disease mechanisms, where infection may persist despite negative tests.

In this context, peptidoglycan could reflect ongoing bacterial turnover—not simply residual debris.

Clinical Implications: Why This Distinction Matters

Understanding whether inflammation reflects persistent infection or post-infectious immune activation is critical for treatment decisions.

If infection persists, suppressing the immune system without addressing the underlying cause may delay recovery or worsen outcomes.

If inflammation is truly immune-driven, unnecessary antibiotic use may expose patients to risk without benefit.

Both scenarios may exist. This could explain why some patients improve with additional antibiotics while others respond better to immune-directed therapies.

Without reliable tools to distinguish between these mechanisms, treatment decisions remain complex and often individualized.

A More Nuanced Understanding

The identification of peptidoglycan advances understanding of Lyme arthritis—but also highlights ongoing uncertainty.

Treating all persistent symptoms as post-infectious may leave some patients undertreated. Treating all patients with extended antibiotics may lead to overtreatment.

A more individualized, evidence-informed approach is needed.

This approach must account for testing limitations, bacterial biology, and variability in patient response.

Clinical Takeaway

Peptidoglycan from Borrelia burgdorferi can persist in joint fluid after treatment and may drive inflammation.

Whether this reflects inert debris or ongoing infection remains unclear. Detecting live bacteria is challenging, and current tests cannot reliably distinguish between these possibilities.

Persistent joint symptoms likely arise from multiple mechanisms. Both post-infectious inflammation and ongoing infection may contribute in different patients.

Careful, individualized evaluation remains essential.

Frequently Asked Questions

Can Lyme disease cause persistent joint pain after treatment?
Yes. Some patients experience ongoing joint swelling and pain even after completing antibiotic therapy. This is sometimes called antibiotic-refractory Lyme arthritis.

What is peptidoglycan and why does it matter?
Peptidoglycan is a structural molecule from the Borrelia burgdorferi cell wall. Its presence in joint fluid after treatment suggests that bacterial material persists and may continue to drive inflammation.

Does peptidoglycan prove the infection is still active?
Not definitively. It may represent leftover debris or ongoing bacterial turnover. Current testing cannot reliably distinguish between these possibilities.

References

Jutras BL, Lochhead RB, Kloos ZA, et al. Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis. Proc Natl Acad Sci. 2019;116(27):13498–13507.
Arvikar SL, Steere AC. Diagnosis and treatment of Lyme arthritis. Infect Dis Clin North Am. 2015;29(2):269–280.
Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med. 1987;107(5):725–731.

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention